Skip to main content

Table 1 Kinase inhibition profile of ABT-869 (with permission adapted from Molecular Cancer Therapeutics 2006;5:995–1006)

From: ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

Related RTKa Non-related TKa Ser/Thr Kinasesb
Kinase IC50 (nM) Kinase IC50 (nM) Kinase IC50 (nM)
KDR 8 SRC > 50,000 AKT > 50,000
FLT1 3 IGFR > 50,000 SGK 940
FLT4 40 INSR > 50,000 CDC2 9,800
PDGFRα 29 LCK 38,000 PKA 5,900
PDGFRβ 25 EGFR > 50,000   
CSF-1R 5 HCK > 50,000   
KIT 20 CMET > 50,000   
FLT3 10 LYN > 20,000   
TIE2 170 FYN > 50,000   
RET 1,900 FGR > 50,000   
FGFR > 12,500     
  1. a. IC50 values determined at an ATP concentration of 1 mM.
  2. b. IC50 values determined at an ATP concentration of 5 to 10 μM.